American Heart Journal
Volume 150, Issue 4 , Pages 681-688 , October 2005

Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology

  • Ruiqin Liu, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Masato Yamamoto, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Masao Moroi, MD, FACP

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Masao Moroi, MD, FACP, Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo 153-8515, Japan.
    • ,
  • Tetsuya Kubota, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Tsuyoshi Ono, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Atsushi Funatsu, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Hiroki Komatsu, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Takahiro Tsuji, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Hidehiko Hara, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Hisao Hara, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Masato Nakamura, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Hironori Hirai, MD

      Affiliations

    • Division of Cardiovascular Medicine, Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Tetsu Yamaguchi, MD

      Affiliations

    • Toranomon Hospital, Minato-ku, Japan

Received 7 April 2004 ,Accepted 13 November 2004.

References 

  1. Saikku P, Mattila K, Nieminen MS, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986
  2. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268:68–72
  3. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000;181:402–410
  4. Mendall MA, Carrington D, Strachan DP, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30:121–128
  5. Dahlen GH, Boman J, Birgander LS, et al. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114:165–174
  6. Shor A, Kuo CC, Patton DL, et al. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158–161
  7. Vink A, Pasterkamp G, Poppen M, et al. The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae. Atherosclerosis. 2001;157:117–122
  8. Maass M, Jahn J, Gieffers J, et al. Detection of Chlamydia pneumoniae with peripheral blood monocytes of patients with unstable angina or myocardial infection. J Infect Dis. 2000;181:449–4451
  9. Ericson K, Saldeen TG, Lindquist O, et al. Relationship of Chlamydia pneumoniae to severity of human coronary atherosclerosis. Circulation. 2000;101:2568–2571
  10. Wong Y, Thomas M, Tsang V, et al. The prevalence of Chlamydia pneumoniae in atherosclerotic and non-atherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol. 1999;33:152–156
  11. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis: the Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med. 1996;125:979–982
  12. Apfalter P, Loidl M, Nadrchal R, et al. Isolation and continuous growth of Chlamydia pneumoniae from atherectomy specimens. Eur J Clin Microbiol Infect Dis. 2000;19:305–308
  13. He H, Prerce GN, Zhong G, et al. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest. 1999;103:747–753
  14. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636
  15. Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Path. 1997;181:93–99
  16. Higuchi ML, Bezerra HG, Palomino S, et al. Adventitial fibrosis and inflammation surrounding atheroma: implications for different arterial remodeling in stable and unstable plaques. J Am Coll Cardiol. 2000;35:3684
  17. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330–335
  18. Danesh J, Collons R. Chronic infections and coronary heart disease: is there a link?. Lancet. 1997;350:430–436
  19. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titers and coronary heart disease: prospective study and meta-analysis. BMJ. 2000;321:208–213
  20. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titers and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:371–375
  21. Shimada K, Mokuno H, Watanabe Y, et al. High prevalence of seropositivity for antibodies to chlamydia-specific lipopolysaccharide in patients with acute coronary syndrome. J Cardiovasc Risk. 2000;7:209–213
  22. Wong BY, Gnarpe J, Teo KK, et al. Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non–ST-elevation acute coronary syndromes. Am Heart J. 2002;144:987–994
  23. Gnarpe J, Sparr A, Naas J, et al. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. APMIS. 2000;108:357–362
  24. Higuchi ML, Castelli JB, Aiello VD, et al. Great amount of C. pneumoniae in ruptured plaque vessel segments at autopsy. A comparative study with stable plaque. Arq Bras Cardiol. 2000;74:149–151
  25. Puolakkainen M, Parker J, Kuo CC, et al. Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Microbiol Immunol. 1995;39:551–554
  26. Mass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827–832
  27. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma—evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785–1790
  28. Murat V, Kalayoglu MV, Libby P, et al. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2731–2734
  29. Wong Y, Thomas M, Tsang V, et al. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol. 1999;33:152–156
  30. Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (starry grading) of associated atherosclerotic plaque. Circulation. 1999;99:2733–2736
  31. Vink A, Poppen M, Schoneveld AH, et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation. 2001;103:1613–1617
  32. Beatty W, Morrison R, Byme G, et al. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994;58:686–689
  33. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 1995;172:585–588
  34. Ong G, Thomas BJ, Manfield OA, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol. 1996;49:102–106
  35. Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J. 1999;138:488–490
  36. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278
  37. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non–insulin-dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17:682–688
  38. Strachan DP, Carrington D, Mendall MA, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischemic heart disease over 13 years in the Caerphilly Prospective Heart Disease Study. BMJ. 1999;318:1035–1039
  39. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403–411
  40. Abdelmouttaleb I, Danchin N, Ilardo C, et al. C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J. 1999;137:346–351
  41. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, et al. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathol. 1994;26:313–319
  42. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620
  43. Godzik KL, O'Brien ER, Wang SK, et al. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol. 1995;33:2411–2414
  44. Knoebel E, Vijayagopal P, Figueroa JE, et al. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun. 1997;65:503–506
  45. Kaukoranta-Tolvanen SS, Ronnl T, Leinonen M, et al. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microbiol Pathol. 1996;21:407–411
  46. Netea MG, Selzman CH, Kullberg BJ, et al. Cellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30:541–549
  47. Geng Y, Shane RB, Berencst K, et al. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. J Immunol. 2000;164:5222–5229
  48. Biasucci LM, Liuzzo G, Ciervo A, et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation. 2003;107:3015–3017
  49. Mayer M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock protein of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock protein as a possible link between infections and atherosclerosis. Circulation. 1999;99:1560–1566
  50. Kol A, Bourcier T, Lichtman AH, et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest. 1999;103:571–577
  51. Kol A, Sulchova GK, lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307
  52. Kreula P, Puolakkainen M, Sarvas M, et al. Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte derived macrophage. Arterioscler Thromb Vasc Biol. 2001;21:E1–E8
  53. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised control trial. Lancet. 2003;361:809–813
  54. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755–1760
  55. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: a randomized control trial. JAMA. 2003;290:1459–1466

 This study was supported in part by the Japan-China Sasakawa Medical Fellowship.

PII: S0002-8703(05)00037-2

doi: 10.1016/j.ahj.2004.11.028

American Heart Journal
Volume 150, Issue 4 , Pages 681-688 , October 2005

Article Tools

* Image Usage & Resolution